Abstract: Background: Psychedelic-assisted therapy is increasingly being explored as potential treatment for substance use disorders (SUDs). While multiple systematic reviews and meta-analyses have examined this topic, the efficacy, methodological quality, and overlap of the existing evidence base remain unclear. Methods: We conducted an umbrella review of systematic reviews and meta-analyses...
The etiology of OCD is complex and appears to involve multiple biological pathways. Imbalances in central serotonin, dopamine, and glutamate activities are widely thought to play a causative role. Despite strong evidence supporting first-line OCD pharmacotherapies, approximately 40-60 % of OCD patients remain unresponsive and are considered treatment resistant (TR). Although a range of agents...
BACKGROUND: The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated clinical and...
Importance Psilocybin use has surged in the US following decriminalization efforts and promising clinical trial results. Mirroring early cannabis legalization, public access and enthusiasm are outpacing regulatory oversight and scientific understanding, posing potential risks to public health. Objective To review emerging evidence on the public health implications of unregulated psilocybin...
Adverse psychiatric symptoms caused by cannabis are a significant concern, and Δ9-tetrahydrocannabinol (THC) has been identified as a key contributor to these symptoms. THC binds to cannabinoid type 1 receptors (CB1Rs), which are abundant in the brain and associated with cognition. The prefrontal cortex (PFC) is crucial for cognitive functions. However, the functions of CB1Rs in the PFC in...
Hexahydrocannabinol (HHC) is a semi-synthetic cannabinoid which was marketed and sold openly in Ireland as a legal alternative to cannabis products until it was controlled in July 2025. There have been reports of psychotic illness precipitated by HHC use. Consequently, there are fears that HHC may become a public health issue. This study's aim was to measure the extent of HHC use and patterns...
The article presents the case of a 16-year-old patient who developed psychosis following prolonged use of tetrahydrocannabinol. The clinical picture is described in detail, including disturbances in perception, cognition, and affect, complemented by information obtained through interviews with the patient and his parents during inpatient psychiatric treatment. The course of cognitive...
This study explores how individuals from ethnoracially marginalized backgrounds engage with psychedelic substances for psychological healing, cultural reconnection, and resistance to structural neglect in mainstream health care systems. Based on 23 in-depth interviews and participant-observation within a psychedelic preparation and integration training program, the research documents how...
Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUDs). Additionally, we aimed...
Research SquareAugust 21, 2025Ritchy Hodebourg, Lillian Duncan, Eric Dereschewitz et al.
preprint
The rising legal acceptance of cannabis and the high comorbidity between cannabis use disorder (CUD) and post-traumatic stress disorder (PTSD) highlight the importance of understanding how stress and cannabis influence the brain. We recently discovered that cannabis use promotes two PTSD-like symptoms: avoidance coping behaviors and the generalization of stress-coping responses to a neutral...